Redwood Pharma AB (publ) today announces that the last patient has now been included in the company’s ongoing Phase II trial of RP101 and that recruitment is thus completed. RP101 is an innovative treatment for chronic dry eyes in postmenopausal women.
Redwood Pharma’s Phase II clinical trial is a randomized, placebo-controlled multicenter study conducted in clinics in Austria, Hungary and Germany. Approximately 100 patients are evaluated during a treatment period of three months, after which the study ends with a follow-up after the last dose has been administered.
The goal is to show